Patents by Inventor Mei Lai

Mei Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20240150354
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: May 9, 2024
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20230255996
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: April 24, 2023
    Publication date: August 17, 2023
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20230241086
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: November 10, 2022
    Publication date: August 3, 2023
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Oral formulations of cytidine analogs and methods of use thereof
    Patent number: 11571436
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: February 7, 2023
    Assignee: CELGENE CORPORATION
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20220105118
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 11292772
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: April 5, 2022
    Assignee: Celgene CAR LLC
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20220079964
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 17, 2022
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20220062280
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 12, 2021
    Publication date: March 3, 2022
    Inventor: Mei Lai
  • Heat conducting device and vehicle with the same
    Patent number: 11254182
    Abstract: A heat conducting device in a vehicle whereby heat in the body or shell of the vehicle is transferred to the ground includes a control device, a heat transferring device, and a driving device. The heat transferring device is in the vehicle and is connected to the shell of the vehicle when the vehicle is flameout, the driving device is coupled to the control device and the heat transferring device, such that the heat transferring device is extended downwards from the vehicle, until the heat transferring device contacts the ground, thereby heat of the shell of the vehicle is transferred to the ground.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: February 22, 2022
    Assignees: Fu Tai Hua Industry (Shenzhen) Co., Ltd., HON HAI PRECISION INDUSTRY CO., LTD.
    Inventor: Dong-Mei Lai
  • Solid forms of an epidermal growth factor receptor kinase inhibitor
    Patent number: 10946016
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 16, 2021
    Assignee: Celgene CAR LLC
    Inventor: Mei Lai
  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20210017137
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: February 21, 2020
    Publication date: January 21, 2021
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20200316099
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 8, 2020
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Isotopologues of 5-azacytidine
    Patent number: 10646503
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20200101095
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 2, 2020
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 10570099
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 25, 2020
    Assignee: Celgene CAR LLC
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • HEAT CONDUCTING DEVICE AND VEHICLE WITH THE SAME
    Publication number: 20190375268
    Abstract: A heat conducting device in a vehicle whereby heat in the body or shell of the vehicle is transferred to the ground includes a control device, a heat transferring device, and a driving device. The heat transferring device is in the vehicle and is connected to the shell of the vehicle when the vehicle is flameout, the driving device is coupled to the control device and the heat transferring device, such that the heat transferring device is extended downwards from the vehicle, until the heat transferring device contacts the ground, thereby heat of the shell of the vehicle is transferred to the ground.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 12, 2019
    Inventor: DONG-MEI LAI
  • Foot massager
    Patent number: D949413
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: April 19, 2022
    Inventor: Chia-Mei Lai
  • Foot massager
    Patent number: D963182
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 6, 2022
    Inventor: Chia-Mei Lai
  • Foot massager
    Patent number: D963874
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 13, 2022
    Inventor: Chia-Mei Lai
  • Foot massager
    Patent number: D963875
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 13, 2022
    Inventor: Chia-Mei Lai